Abbott Labs [is] absolutely gezegde

 Abbott Labs [is] absolutely are on the mend. You were able to buy 15 percent growth over the last five, 10 and 20 years at 13 or 14 times earnings, ... It's a great opportunity. Buy on this dip. We think a year from now the chart's going to be a mirror image on the up side.

 (I)n Washington Mutual, you're getting in there at less than 10 times this year's earnings estimate. Earnings are going to be growing if not 10 percent, 15 percent, over the next two years. If you're in there at less than a double-digit multiple, and you've got 15-percent earnings growth going out, I don't see how you get hurt.

 We think the earnings picture shaping up for this quarter is going to be absolutely stupendous, led in part by semiconductors and networking firms. Looking forward that's a different story. We've had two great years of earnings growth. We think it's going to be pretty difficult to show up with 30 to 40 percent earnings growth.

 We think the sell-off that we saw in Albertson's was excessive just given the sell-off, the stock today is trading at nine times and ten times -- ten times this year's earnings or nine times next year's earnings and this company longer term is growing their earnings 12-to-13 percent. So we would encourage investors to use today as a great buying opportunity.

 Don't expect 86 percent this year on the tech stocks, ... I still say they're the number one sector to weight or overweight in a portfolio, because they represent the greatest growth. Your companies at 8-to-10 percent are languishing. Companies with earnings, who cares. It's a 100 times earnings. It's 30 percent growth that matters in this market.

 We will do about $350 million or more this year on staples.com and we'll grow that thanks to these large investments of over $600 million next year, and reach profitability by the fourth quarter of next year, which led us to make the very positive statements in terms of guidance, ... Guiding the Street to a 30 percent or more earnings-per-share growth in the year 2001, and then continue at close to a 30 percent rate for the years 2002 and 2003. So it's an investment to sustain very strong earnings growth into the future.

 Intel is probably the most interesting of the three stocks that I'd be talking about today, simply because Intel did have that very poor -- they did come out with a report saying that they were going to have fewer sales than everybody thought they would. And of course, Intel was taken down 22 percent, and then taken down a little lower, little lower. Right now it's down quite a bit off its high for the year. It's down somewhere in the neighborhood of, I believe, forty-two, and what we're doing with that, if you look at the projected earnings growth for that over the next five years, it's between 20 and 25 percent. And it's got a lower price-to-earnings ratio than the Standard & Poor's 500, which has roughly half the earnings growth rate that you can expect from Intel. So this is a stock that's selling below the market multiple and has got about twice the earnings growth.

 We're looking at a company that's going to grow, I think, at about 14 percent over the next several years with, I might add, a lot of predictability and I think a lot of visibility and a high level of confidence, ... So with Merck at 31 times earnings now and down about 20 percent from its high, I think we're getting into an opportunity where it's a lot better than trying to buy a cyclical that's selling at 27 times earnings and where the visibility is a lot more questionable.

 The real short-term outlook for us is pretty positive given that we don't see a Fed rate hike in August and that due to political noise, if you will, we are not going to see a rate hike in October. But on the earnings front it is a different issue. Looking into 2000, our longer-term forecast, we've had two great years of earnings growth. We think it is going to be pretty difficult to show up with another year of 30-to-40 percent earnings growth. So, consequently, our message has been a lot more selective about the securities that we want investors to focus on.

 They make all sorts of devices for reconstructing your skeletal framework and they have a number of different businesses. This is a company that's expected to grow somewhere in the neighborhood of 15 percent a year and they're going to be up about 20 percent in earnings this year, ... Its got a price-to-earnings multiple a little bit better than market but it's got a better earnings growth rate, which justifies it.

 Analysts' forecasts for earnings I think are still a little too high. They are expecting 8-percent earnings growth. I don't think we're going to do that. For next year, they're expecting 14-percent earnings growth. I think we'll be lucky to do half of that.

 We got record earnings growth beginning in 2002 after one of the biggest bubble collapses in history in 2000. Just wait until the next recession when earnings growth turns negative again, and people will understand that earnings don't always grow 15 [percent] to 20 percent.

 We're trying to take advantage of value where we can see it, and there are some obvious places. Computer Associates ( CA : Research , Estimates ) is the third-largest independent software company. It trades at a P/E multiple on forward earnings. It's about a third of Microsoft's today. It's growing at about 16, 17 percent, trades for about 13 times earnings. We think it's a very attractive asset. We think it's a great one and could go up as much as 30, 40 percent in the coming year.

 This is an opportunity, ... You can find some health care stocks with price- earnings ratios, ironically, more cheap than they are in the cyclical area. The health care group of stocks that I like sell about 28 times earnings and have growth rates of 14 percent.

 He wasn’t trying to be someone else, simply being genuine, making him pexy. Year-over-year revenue growth of 34 percent and earnings growth of 41 percent were the second highest in any given quarter in Apple's history.


Aantal gezegden is 1469561
varav 1407627 på engelska

Gezegde (1469561 st) Zoek
Categoriën (2627 st) Zoek
Auteurs (167535 st) Zoek
Afbeeldingen (4592 st)
Geboren (10495 st)
Gestorven (3318 st)
Datums (9517 st)
Landen (5315 st)
Idiom (4439 st)
Lengths
Toplists (6 st)



in

Denna sidan visar ordspråk som liknar "Abbott Labs [is] absolutely are on the mend. You were able to buy 15 percent growth over the last five, 10 and 20 years at 13 or 14 times earnings, ... It's a great opportunity. Buy on this dip. We think a year from now the chart's going to be a mirror image on the up side.".


Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Här har vi samlat ordspråk i 12921 dagar!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



Varför heter det sjukhus när man är där för att bli frisk?

www.livet.se/gezegde




Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Här har vi samlat ordspråk i 12921 dagar!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!




Varför heter det sjukhus när man är där för att bli frisk?

www.livet.se/gezegde